Results 1 to 10 of about 293,895 (310)
Landscape of inflammatory bowel disease in Singapore [PDF]
Intestinal Research, 2022 Inflammatory bowel disease (IBD), primarily Crohn’s disease and ulcerative colitis, had been widely recognized to affect the Western population. However, the notable rise in prevalence of IBD in Asia, including Singapore, had garnered much attention to ...
Daren Low +3 more
doaj +1 more source
Diagnostics, 2021 Iron deficiency (ID) is a common manifestation of inflammatory bowel disease (IBD), arising primarily due to chronic inflammation and/or blood loss. There is no gold standard for ID diagnosis, which is often complicated by concomitant inflammation.
Eleni Leventi +4 more
doaj +1 more source
Flipside of the Coin: Iron Deficiency and Colorectal Cancer
Frontiers in Immunology, 2021 Iron deficiency, with or without anemia, is the most frequent hematological manifestation in individuals with cancer, and is especially common in patients with colorectal cancer.
Aysegül Aksan +11 more
doaj +1 more source
Colitis evolving into ulcerative colitis [PDF]
Gut, 2005 We observed the development of ulcerative colitis (UC) in a 37 year old young woman with clinical and histological features of lymphocytic colitis (LC) after a period of six years. Seven years ago, the patient was admitted to our gastroenterology unit complaining of watery diarrhoea (⩾6 stools/day). She had never smoked and she was not taking any drugs
CALABRESE, CARLO +2 more
openaire +1 more source
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis [PDF]
Intestinal Research, 2021 Background/Aims Infliximab (IFX) has proven effective as rescue therapy in steroid-refractory acute severe ulcerative colitis (ASUC), however, the long-term real-world data are scarce.
Shin Ju Oh +10 more
doaj +1 more source
Current Research in Pharmacology and Drug Discovery, 2022 The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules.
Pascal Juillerat +5 more
doaj +1 more source
Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
Frontiers in Medicine, 2022 In recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumor histology or baseline mutations, sometime in patients without any alternative of treatment.
Virginia Robles-Alonso +3 more
doaj +1 more source
BMC Medical Ethics, 2019 Background Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years.
Orna Ehrlich +3 more
doaj +1 more source
Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis
Cells, 2020 PNAd and MAdCAM-1 addressins on venules are of importance in T-cell homing and potential therapeutic targets in ulcerative colitis (UC). Normally, PNAd+ high endothelial venules (HEVs) are only present in lymphoid organs, whereas small numbers of MAdCAM ...
Britt Roosenboom +10 more
doaj +1 more source
Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report
Frontiers in Immunology, 2022 Infliximab, a chimeric monoclonal antibody against anti-tumor necrosis factor-α (TNF-α), has revolutionized the management of inflammatory bowel disease. However, a recent nested case-control study showed that anti-TNF-α therapy exposure in patients with
Shin Ju Oh +3 more
doaj +1 more source